The prognosis of osteosarcoma, not only localized but also with limited lung metastasis, has remarkably improved through intensified chemotherapy and surgical resection. However, patients who have bone metastases or multiple lung metastases still have a poor prognosis. High-dose chemotherapy with autologous SCT (auto-SCT) has also been performed with unsatisfactory outcome for advanced or relapsed osteosarcoma. 1, 2 In the treatment of hematologic malignancies and certain forms of solid tumors, allogeneic SCT (allo-SCT) has been shown to offer the potential for applying marrow ablative doses of chemoradiotherapy, as well as inducing a curative graft-versustumor (GVT) effect. We report here a case of metastatic osteosarcoma successfully treated with allogeneic BMT (allo-BMT) from an HLA-identical sibling.
A 6 year-old Japanese boy was admitted in September 1999 with persistent fever and right knee pain. Laboratory tests revealed marked elevations of serum alkaline phosphatase (11 700 IU/l) and lactic dehydrogenase (904 IU/l). His right knee was markedly swollen, and T2-weighted coronal magnetic resonance image of the right femur showed a large distal tumor with invasion into soft tissues and the marrow cavity. Chest radiograph and computed tomographic scan revealed multiple abnormal nodules in bilateral lungs (Figure 1a ). Technetium-99 methylene diphosphonate bone scintigraphy showed abnormally strong uptakes at the distal site of the right femur, proximal site of the right tibia and right ankle (Figure 1b) . He was diagnosed with osteosarcoma with multiple metastases of lung and bone based on biopsy findings of his right distal femur. After the first course of chemotherapy consisting of high doses of methotrexate, ifosfamide, bleomycin, adriamycin, and cisplatin (T-20 Rosen protocol), swelling of the primary lesion was dramatically reduced, and amputation of his right lower limb 6 cm below the lesser throcanter was subsequently performed. The resected specimens revealed an abundance of necrotic tissues without viable tumor cells at the amputated edge (grade IV chemosensitivity). As pulmonary metastatic nodules remained unchanged even after the second course of chemotherapy, thoracotomy was performed and a total of 43 nodules were surgically resected from bilateral lobes. A majority of the small nodules in the lungs were left unresected. Apparently viable cells were evident in at least two resected nodules. After the third course of chemotherapy, and in an attempt to achieve remission through a GVT effect, he received allo-BMT in January 2000 from an identically matched (HLA-A24/31, -B 55/61, -DR4/6) younger sister as the donor. A total of 3.9 Â 10 8 /kg of nucleated bone marrow cells were infused after administration of TBI (1200 cGy in six fractions) from day À6 to day À4, VP-16 500 mg/m 2 i.v. on day À3, and thiotepa 600 mg/m 2 once daily i.v. from day À3 to day À2. Prophylaxis for GVHD consisted of CsA (3 mg/kg/day, i.v.) and short-term MTX (12 mg/m 2 on day 1 and 8 mg/m 2 on days 3, 6, and 11). Recombinant human G-CSF was given from day 4 and ANC reached 0.5 Â 10 9 /l on day 14. The last platelet transfusion was performed on day 18. FISH analysis of his PBL demonstrated that 99.4% of the cells were of XX chromosome. Grade II GVHD (stage three skin rash and stage one diarrhea) developed on day 14, resolved once by prednisolone p.o. (2 mg/kg/day), but gradually exacerbated to grade III (90% of skin) from day 48. The skin rash subsided gradually after tacrolimus (0.015 mg/kg/day, i.v.) was initiated on day 59, but persisted for almost 2 years. Administrations of tacrolimus and prednisolone were slowly withdrawn and finally stopped on days 346 and 516, respectively. This patient is alive and without any evidence of relapse 67 months after BMT.
Antigens capable of serving as targets for a GVT effect after HLA-matched allo-SCT are mHAs and cancer antigens. CD8 þ CTLs recognize these antigens presented as small peptides in the groove of HLA class I molecules. In contrast to neuroblastoma, primary osteosarcoma cells and cell lines are known to possess considerably high levels of HLA class I antigen expression, 3 suggesting that osteosarcoma can at least express a variety of mHAs. mHAs are peptides of limited polymorphism encoded by genes on the Y-chromosome or by autosomal genes, and show either ubiquitous or restricted tissue expression. To date, six human H-Y epitopes on the Y-chromosome restricted to HLA-A1, A2, B7, B8, B60, and DQ5 have been reported. Although known H-Ys are not expressed in our patient's HLA types, some H-Ys not clarified yet might play a role as one of mHAs in our patient. As H-Ys are ubiquitously expressed in human tissues, these mHAs are expected to be the targets for both GVHD and GVT effect. 4 In fact, Gratwohl had reported that male recipients of female marrow are at an increased risk for GVHD and benefit for GVL effect when compared with other donor/ recipient gender combinations. 5 A variety of human cancer antigens, the other targets of GVT effects, are also restricted by HLA-class I. Of these, MAGE family antigens originally identified in melanomas are highly expressed in osteosarcoma cell lines and fresh tumor tissues. 6 HLA-A24 restricted SART1 and SART3 antigens are also detected in osteosarcoma. 7, 8 In fact, SART3-derived peptides are reported to induce HLA-A24-restricted specific-specific CTLs from PBL of osteosarcoma patients. 8 These cancer antigens could also be the targets for a GVT effect in our HLA-A24 positive patient.
According to previous reports, 1,2 3-year survival rates after auto-SCT for metastatic and relapsed osteosarcoma were only 12-20%. We thus attempted allo-SCT to elicit a GVT effect against osteosarcoma cells in our patient. Only two cases of allo-BMT from HLA matched siblings (HLA types not described) for relapsed osteosarcoma have been previously reported. 9, 10 Both were sex-matched transplants using nonmyeloablative conditioning regimen, and tumors only transiently regressed. To our knowledge, this is the first reported case of successful treatment of metastatic osteosarcoma by allo-BMT. An optimal combination of total-cell-kill oriented conventional conditioning, suitable donor/recipient gender combination, and/or specific HLA types capable of expressing specific mHAs might be required to elicit the maximum GVT effect, and more cases will be needed to evaluate the effectiveness of allo-SCT against this disease. 
